AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
253.52B
Market cap253.52B
Price-Earnings ratio
23.45
Price-Earnings ratio23.45
Dividend yield
1.98%
Dividend yield1.98%
Average volume
5.23M
Average volume5.23M
High today
$162.71
High today$162.71
Low today
$160.25
Low today$160.25
Open price
$160.48
Open price$160.48
Volume
2.45M
Volume2.45M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$145.79
52 Week low$145.79

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $161.82. The company's market cap stands at 253.52B, with a P/E ratio of 23.45 and a dividend yield of 1.98%.

On 2026-08-10, AstraZeneca(AZN) stock moved within a range of $160.25 to $162.71. With shares now at $161.82, the stock is trading +1.0% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 2.45M, compared to an average daily volume of 5.23M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

AZN News

Axios 3d
$400B AstraZeneca-Bristol Myers Squibb merger rumor draws market reaction - Axios

...

$400B AstraZeneca-Bristol Myers Squibb merger rumor draws market reaction - Axios
TipRanks 3d
AstraZeneca: Buy Rating Reiterated on Attractive Valuation, Robust Pipeline, and Unchanged $16,500 Price Target

Analyst Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca and keeping the price target at p16,500.00. Claim 55% Off TipRanks Un...

TipRanks 5d
No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal

Shares in British pharma giant AstraZeneca (AZN) jumped about 5% on Wednesday morning while those in top U.S. biopharma company Bristol Myers (BMY) fell by more...

Analyst ratings

87%

of 30 ratings
Buy
86.7%
Hold
10%
Sell
3.3%

More AZN News

Nasdaq 5d
Reminder - AstraZeneca Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel , on 8/7/26, AstraZeneca plc (Symbol: AZN) will trade ex-dividend, for its semi-annual dividend o...

Reminder - AstraZeneca Goes Ex-Dividend Soon
Seeking Alpha 5d
Bristol-Myers falls on report there are no talks going on with AstraZeneca

Bristol-Myers Squibb (BMY) dropped 1.4% in premarket trading after a report that there are no discussions happening with AstraZeneca (AZN) about a potential dea...

Bristol-Myers falls on report there are no talks going on with AstraZeneca
MarketWatch 5d
AstraZeneca stock jumps and Bristol Myers shares fall on report of 'no discussions'

A Reuters story that there are no discussions between AstraZeneca and Bristol Myers Squibb had the affect of sending the U.K.-headquartered pharma giant 4% high...

AstraZeneca stock jumps and Bristol Myers shares fall on report of 'no discussions'
TipRanks 5d
CSPC Pharmaceutical Group Secures US$10 Million Milestone From AstraZeneca

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 6d
AstraZeneca’s Eluminate-3 Trial Targets New Diabetes Growth Path

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...

TipRanks 6d
AstraZeneca Advances Early Combo Study With AZD0780 and AZD4954, Signaling Steady Pipeline Progress

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...

Barron's 6d
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open

Biotech and Pharma Feature AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open In this article BMY 524715 LLY AZN ABBV Bristol Myers Squibb a...

AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.